UBE2N interacts with BRCA1, and its expression serves as a potential biomarker of response to poly(ADP-ribose) polymerase (PARP) inhibitors and other DNA-repair-targeted therapies in breast cancer (54). Here, UBE2N is linked to breast carcinoma.